Variants of SARS-CoV-2 in Central and West Africa: Frequency of Circulating Viruses and Implications for the Management and Control of the Pandemic
Trial Snapshot
- Phase
- Not Applicable
- Enrollment
- 12,600
- Locations
- 6
- Primary Endpoint
- Number of SARS-CoV-2 sequences generated partially and in whole genome
Study Overview
Brief Summary
The main objective of this research is to identify and characterize the different molecular variants of SARS-CoV-2, emerging and / or circulating in several countries of Sub-Saharan Africa (Burkina Faso, Côte d'Ivoire, Gabon, Mali, Chad and Republic of Congo) and determine their role in the evolution of the pandemic.
Detailed Description
The main objective of this research is to identify and characterize the different molecular variants of SARS-CoV-2, emerging and / or circulating in several countries of Sub-Saharan Africa (Burkina Faso, Côte d'Ivoire, Gabon, Mali, Chad and Republic of Congo) and determine their role in the evolution of the pandemic.
The research will combine retrospective and prospective approaches to determine the evolutionary dynamics of the virus since the start of the pandemic. It is planned to sequence the entire Spike protein gene for 1550 viruses and make 300 entire genomes. This work will be supplemented by antibody seroneutralization and respiratory transcriptomics tests, in order to estimate the immuno-virological response of the COVID-19 disease associated with the identified SARS-CoV-2 variants.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Other
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Major subject (cf. country)
- •Presenting for a SARS-COV-2 diagnosis, whether symptomatic or not
- •Not objecting to participating in the research
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Number of SARS-CoV-2 sequences generated partially and in whole genome
Time Frame: Through study completion, an average of 1 year.
This outcome represent our main gaol and will include sequences that were partially generated in the Spike proteine and full genomes as well. Our current target is 1550 sequences.
Secondary Outcomes
- Number of new SARS-CoV-2 variants identify(Through study completion, an average of 1 year.)
- Number of individuals tested positive for COVID-19(Up to six months)